



## STELLAR MEDICINES FOR RARE DISEASES


Eride Quarta, Pharm D; PhD  
<http://plumestars.com>  
[info@plumestars.com](mailto:info@plumestars.com)

An effective targeted cancer therapy

# PROBLEM

Malignant Pleural Mesothelioma (MPM) is a very aggressive pleura and peritoneum cancer and there is very high risk of local recurrence after surgery.

Patient have 12 months survival after diagnosis.

A light gray world map is centered in the background of the slide, showing the continents of North America, South America, Europe, Africa, Asia, and Australia.

**50.000 patients**

**43.000 people die  
every year  
worldwide**

**9.000 cases/year in China**

# THE BIG IDEA

**Development of novel medicine  
repurposing in  
innovative targeted delivery systems  
drugs used to cure  
Malignant Pleural Mesothelioma**

# Solution: HYALCIS

Hyalcis is a biodegradable film loaded with **cisplatin** and sodium hyaluronate.

The film is deposited in the thorax cavity after surgery for primary tumor resection, with the objective to release **cisplatin in loco** to prevent or delay the local metastases of MPM.



**Thickness** :60-120  $\mu\text{m}$

**Size**: 10x10 cm


# HYALCIS BENEFITS

Expectancy life increased  
Unique targeted *in situ* treatment

Untreated

Hyalcis film treatment

Cisplatin solution



Efficacy: **Significant reduction** of local tumor metastases

Liver and renal **toxicity lower** than IV administration


# EXISTING ALTERNATIVES

Currently on the market there are **no product for in situ treatment** of malignant mesothelioma.

Alternative solutions include:

- 1 Radiotherapy, which remains a palliative method.
- 2 Intravenous cisplatin chemotherapy with some efficacy but strong adverse effects due to toxicity.
- 3 Intracavitary chemotherapy, still under test but with similar results as IV.

# DEVELOPMENT PLAN



# EARLY ADOPTERS AND CUSTOMERS



Thoracic surgery  
departments in  
hospitals



Pharmaceutical company  
interested in  
anticancer drug


# BUSINESS MODEL:CHANNELS

Find partners  
to co-develop  
the technology

Continue  
development  
internally and  
bring to  
market

Sell or license  
IP to pharma  
industrial partner  
on the base of  
lump sum and  
royalties

# FINANCIAL OVERVIEW



# WHO WE ARE

The pharmaceutical technology researchers of PLU are world recognized and patent owners in medicines constructed on drug delivery technology



**Prof. Paolo Colombo, PhD**  
CEO, Founder  
96 patents



**Prof. Francesca Buttini, PhD**  
Founder  
4 patents



**Anna Giulia Balducci, PhD**  
Founder  
2 patents



**Prof. Ruggero Bettini, PhD**  
Founder  
20 patents



**Eride Quarta, PhD**  
Assistant Professor  
2 patents



**Fabio Borella**  
Co-Founder  
Marketing Manager  
10 patents



**Laura Monica**  
Administrative  
Secretariat



*“This film would revolutionize the quality life of patients”*

Dr. Luca Ampollini, Thoracic Surgeons, Parma Hospital (IT)

STELLAR MEDICINES  
FOR RARE DISEASES

Eride Quarta, Pharm D; PhD  
Paolo Colombo, Pharm D; CEO  
<http://plumestars.com>  
[info@plumestars.com](mailto:info@plumestars.com)